Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday.

Several other equities research analysts have also recently weighed in on ABEO. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, November 25th.

Abeona Therapeutics Stock Down 0.4 %

Shares of NASDAQ ABEO opened at $5.61 on Tuesday. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The firm has a market capitalization of $243.87 million, a price-to-earnings ratio of -2.09 and a beta of 1.44. The stock has a 50 day moving average price of $6.08 and a 200 day moving average price of $5.58. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its holdings in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 2,434 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Abeona Therapeutics in the 3rd quarter worth $84,000. Charles Schwab Investment Management Inc. purchased a new position in Abeona Therapeutics during the 3rd quarter worth $151,000. XTX Topco Ltd acquired a new position in Abeona Therapeutics during the 3rd quarter valued at about $160,000. Finally, JPMorgan Chase & Co. raised its stake in Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 28,606 shares during the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.